Both PL and AP affected multiple pathways however a clear distinction could be drawn for PL which targeted pathways including ELF2 signalling (P = 2.04E-08), mTOR signalling (P = 7.57E-03), and the regulation of elf4 and p70S6K (P = 2.24E-02) while AP affected pathways such as hepatic fibrosis (P = 7.88E- 05), PXR/RXR activation (P= 3.86E-03), atherosclerosis signalling (P = 2.33E-02), and androgen biosynthesis (P = 1.52E-02) (Figure S1). The gene discussed is MTOR; the disease is Hepatic fibrosis.